A New α5β1 Integrin-Dependent Survival Pathway Through GSK3β Activation in Leukemic Cells

Fabienne De Toni-Costes1,2, Mathieu Despeaux1,2, Jessica Bertrand1,2, Ezzeddine Bourogaa1,2, Loïc Ysebaert1,2,3, Bernard Payrastre1,2, Claire Racaud-Sultan1,2*

1 Unite 563, Institut National des Sciences et de la Recherche Medicale, Toulouse, France, 2 Université Toulouse III Paul-Sabatier, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France, 3 Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Service d’Hematologie, Toulouse, France

Abstract

Background: Cell survival mediated by integrin engagement has been implicated in cell adhesion-mediated drug resistance. We have recently demonstrated that the activation of glycogen synthase kinase 3 β (GSK3β) is a new pathway supporting the chemoresistance of leukemic cells adhered to fibronectin.

Methodology and Principal Findings: We show here that in conditions of serum starvation, the fibronectin receptor α5β1 integrin, but not α4β1, induced activation of GSK3β through Ser-9 dephosphorylation in adherent U937 cells. The GSK3β-dependent survival pathway occurred in adherent leukemic cells from patients but not in the HL-60 and KG1 cell lines. In adhesion, activated GSK3β was found in the cytosol/plasma membrane compartment and was co-immunoprecipitated with α5 integrin, the phosphatase PP2A and the scaffolding protein RACK1. PP2A and its regulatory subunit B regulated the Ser-9 phosphorylation of GSK3β. In adherent leukemic cells, α5β1 integrin but not α4β1 upregulated the resistance to TNFα-induced apoptosis. Both extrinsic and intrinsic apoptotic pathways were under the control of α5β1 and GSK3β.

Conclusions and Significance: Our data show that, upon serum starvation, α5β1 integrin engagement could regulate specific pro-survival functions through the activation of GSK3β.

Introduction

The glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein kinase that is involved in many physiological processes, playing important roles in glucose metabolism, cell cycle division, cell adhesion and apoptosis. Derepression of GSK3β activity is implicated in the pathogenesis of neurodegenerative and metabolic disorders, but also in cancer [1]. GSK3β is constitutively active under its Tyr-216 phosphorylated form and regulates many intracellular signaling pathways. At the post-translational level, the function of GSK3β is inhibited through phosphorylation of the Ser9 residue by other protein kinases, including Akt, in response to insulin and growth factors [2].

Following integrin engagement, both inhibition and activation of GSK3β have been described. GSK-3β is inhibited by Ser-9 phosphorylation by the ILK/Akt and Cdc42/PKCζ pathways to promote integrin-mediated cell proliferation or migration, respectively [3,4]. Conversely, cell adhesion to a 3D collagen matrix through α5β1 engagement promotes activation of GSK3β as well as protein phosphatase 2A (PP2A) [5]. PP2A has been previously shown to reactivate GSK3β through dephosphorylation of Ser-9 [6,7]. However, no role has been ascribed to the activated form of GSK3β downstream of integrin engagement.

We have previously shown that GSK3β activation promotes the chemoresistance of adherent leukemic cells on fibronectin or on osteoblasts under serum starvation [8]. The endosteal niche supports chemoresistant leukemic stem cells [9] and is thought to be rich in fibronectin and hypoxic [10]. Adhesion of serum-starved leukemic cells to fibronectin through α5β1 and α5β1 engagement allows both Ser-9 dephosphorylation of GSK3β and NF-κB activation [8]. Others and we have demonstrated that GSK3β can upregulate cell survival through epigenetic and IkB-independent control of NF-κB activity [8,11–14]. Strikingly, the anti-apoptotic role of GSK3β has been demonstrated in different tumors and may involve resistance to death receptor-induced apoptosis [15–20]. Recently, GSK3β was found associated with DDX3 and c-IAP-1 in a death antagonizing signaling complex at death receptors and the resistance to apoptosis was overcome by GSK3 inhibitors [21]. A mitochondrial-mediated cell death was also found regulated by GSK3 [22].

Adhesion to fibronectin through α5β1 and α5β1 engagement supports cell adhesion-mediated drug resistance (CAM-DR) of many tumors [23]. Different specific fibronectin domains are bound by α4β1 and α5β1 integrins and could each induce opposing effects on cell survival and proliferation [24]. The aim of our study was thus to determine the respective roles of α5β1 and α5β1 in...
GSK3β activity in serum-starved adherent leukemic cells. Our results demonstrate that α4β1 but not α2β1 regulates a signaling pathway leading to GSK3β activation and cell survival.

Materials and Methods

Antibodies and pharmacological inhibitors

Monoclonal antibodies against GSK3β, fliotillin and RACK1 were from BD Transduction Laboratories. Monoclonal antibodies GSK3α/β, actin and integrin subunits (α2, P1D6; α5, P4G9) were purchased from Upstate or Biosource International (Camarillo, CA, USA), Sigma and Dako (Carpinteria, CA, USA), respectively. Monoclonal antibodies against α2 subunit (clone JBS5), Akt and caspases were from Chemicon International, Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Cell Signaling technology (Beverly, MA, USA), respectively. Polyclonal antibodies directed against PP2A-A (catalytic subunit of PP2A) and PP2A tyrosine phosphorylated at position 307 were from Santa Cruz Biotechnology, and those against integrin subunits (α4 and α5) came from Chemicon International. Polyclonal antibodies directed against PP2A-B’ (regulatory subunit of PP2A) cytochrome C, GSK3α/β serine phosphorylated at position 21/9 and Akt threonine phosphorylated at position 308 were from Cell Signaling Technology. Polyclonal antibody against p85 was from Upstate. Horseradish-peroxidase-conjugated secondary antibodies against mouse, rabbit or goat were from Cell Signalling Technology. Okadaic acid, a PP2A inhibitor, and the GSK3β inhibitor SB216763 were from Sigma. For Western blotting after immunoprecipitation, GSK3β (monoclonal from BD Transduction Laboratories) and P(ser9)GSK3β (polyclonal from Abcam) antibodies have been biotinylated in our laboratory.

Cells and cell culture

The human leukemic cell lines U937, HL-60 and KG1 were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). U937 and HL-60 cells were grown at 37°C in 5% CO2 in RPMI-1640, containing 10% FCS, 50 μg/ml penicillin, and 50 μg/ml streptomycin. KG1 cells were grown in the same conditions in IMDM 20% FCS. Bone marrow leukemic cells from patients with acute myeloid leukemia (AML) were obtained upon informed consent and processed for their conservation as described previously [8]. Leukemic samples were characterized at the Hematology Department of Toulouse University Hospital (France), classified along Fench American British (FAB) classification [FAB0: undifferentiated AML; FAB1: myeloblastic AML; FAB2: myeloblastic with differentiation AML; FAB4: myelomonocytic AML; FAB5: monocytic AML]. The samples contained more than 80% leukemic blasts after processing. After thawing, viable cells from patients were checked by blue trypan labelling, resuspended in IMDM, then washed once and quickly used for in vitro experiments.

Transfection of siRNA

U937 cells were transfected using the Amaxa nucleofection technology (Amaxa, Koeln, Germany), as indicated in [8]. 6 × 10^6 U937 cells in 100 μl solution V were mixed with 200 nM siRNA GSK3β, 100 nM siRNA PP2A-B’ or with 100–200 nM non-targeting siRNA (Dharmacon Inc., Lafayette, CO, USA). For siRNA integrin, two sources have been used to target α4 and α2 subunits: Ambion (30 nM) and Qiagen (50 nM). Cells were immediately nucleofected with an Amaxa Nucleofector apparatus (Amaxa, program V01), then transferred into wells containing 37°C prewarmed culture medium in six-well plates. After transfection, cells were cultured from 24 to 96 h before analysing by Western blotting or FACS. Decrease of GSK3β and α4 integrin subunit was maximal at 48 h and maintained at 72 h whereas decrease of PP2A-B and α5 integrin subunit was maximal at 72 h. Therefore, survival tests and Western blot analysis were performed at 72 h post-nucleofection.

Western blotting

For Western blotting, 0.5–1 × 10^6 cells washed in Phosphate Buffer Saline (PBS) were denatured in Laemmli sample buffer. After sonication for 10 seconds and boiling for 10 min, proteins were resolved on polyacrylamide SDS gels (SDS–PAGE) and transferred to nitrocellulose (membrane Hybond-C super, Milli-pore). The membrane was blocked for 1 h at room temperature in Tris-buffered saline (TBS) containing 5% fat-free milk and then was probed overnight at 4°C with the appropriate monoclonal or polyclonal antibodies in TBS, 0.1% Tween, 5% fat-free milk and 3% Bovine Serum Albumin (BSA, Euromedex). After incubation for 1 h at room temperature with either anti-mouse or anti-rabbit IgG antibody coupled to horseradish peroxidase, or streptavidin-HRP, detection was achieved using a chemiluminescent substrate (SuperSignal, Amersham Pharmacia Biotech).

Survival and adhesion assays

We have previously set-up a protocol to study the survival pathway in leukemic cells strictly dependent on the integrin engagement without extrinsic growth factors that should not be found in the leukemic niche [8]. Thus, adhesion assays and treatments of cells were performed during 5 h of serum starvation followed by re-addition of serum to discard serum deprivation-linked cytotoxicity, and cell viability was measured at 24 h. Since adhesion under serum-starved conditions was required to trigger GSK3β activation downstream of integrin engagement (pilotary experiments not shown), we have thus measured the differential of GSK3β-linked cell survival between suspension and adhesion upon serum-starved conditions. Half of a 96 well microtiter plate [Maxisorp Immuno Plate, Nunc, Denmark] was coated overnight at 4°C with 40 μg/ml of human fibronectin (Roche Molecular Biochemicals, Mannheim, Germany) in a final volume of 50 μl in PBS, and subsequently incubated with 1% fatty acid-free BSA in PBS to block non specific adhesion sites, 1 h at room temperature. Leukemic cells were diluted to 0.3 × 10^6/ml, left overnight (cell lines) or immediately processed after thawing (AML cells, protocol described below) and then serum-starved for 1 h, incubated or not with okadaic acid (100 nM) or SB216763 (10 μM). Then, cells were allowed to adhere on fibronectin-coated microtiter 96 well plates (0.8 × 10^5 cells/well) for 1 h at 37°C or maintained in suspension. Where shown, leukemic cells in suspension or adhesion were treated with 10 ng/ml TNFα for 4 hours after which cells were washed and incubated in serum-containing medium for 24 h at 37°C. Cell viability was then quantified by methyl thiazolyl tetrazolium (MTT) assay (Sigma). In some experiments, leukemic cells were allowed to adhere on a surface coated with α2- or α5-specific antibodies (clones P4G9, P1D6, JBS5: 1, 0.1 μg/ml and 0.2 μg/ml for optimal adhesion, respectively) as previously described in [8]. Assays were performed in triplicate. For the quantification of cell adhesion, adherent cells were washed in PBS, fixed with a Karnovsky solution and stained with 0.1% crystal violet solution.

For the apoptosis assay, 1 × 10^6 U937 cells treated with control, GSK3β or integrin siRNAs were processed as described for the survival assay and at 5 h of incubation were washed with 1x PBS and then incubated 15 min at room temperature with a FITC-labeled Annexin V/propidium iodide solution (Sigma). These cells were directly analysed in a FACScan (Becton Dickinson) with a
Figure 1. Implication of GSK3β, α4β1, and α5β1 integrins in the survival of adherent leukemic cells. A: 72 hours after nucleofection of siRNA directed to GSK3β, α4 or α5 subunits, U937 were serum starved, adhered to fibronectin, and then underwent a survival assay 24 hours later with MTT (left panel, n = 6, mean ± S.E.M.) or 5 hours later with annexin-PI labeling (right panel, n = 4, mean ± S.E.M.). In MTT assays, data are expressed as...
percentage of survival compared to the non-targeting siRNA (SIC) in suspension. Statistical analysis on compared adhesion/suspension controls and SIC/SiGSK3 or SiC/SiIntegrin in adhesion; *P<0.05, **P<0.01, ***P<0.001. B- The adhesive capacity of siRNA- or SB216763-treated U937 was measured by colorimetry (left panel, n=3, mean ± S.E.M). SiRNA efficacy against GSK3β, α4β1 and α5β1, was checked by Western blot (right panel, representative of three independent experiments). C- Survival assay (MTT) was performed as described in Material and Methods with the leukemic cell lines U937, HL-60, KG1 (n = 3, mean ± S.E.M) and the leukemic cells from patients (n = 8, mean ± S.E.M. 1 FAB0, 3 FAB1, 1 FAB2, 1 FAB4, 2 FAB5) after treatment with the GSK3β inhibitor, SB216763 (10 μM). Variations of cell survival in cells treated by SB216763 compared to the untreated cells in suspension or in adhesion are shown: **P<0.01, ***P<0.001. D- Variations of the Ser-9 phosphorylation of GSK3β upon adhesion on fibronectin of U937, HL-60, KG1 and AML patient cells (FAB 5) are shown. Representative of three independent experiments.

doi:10.1371/journal.pone.0009807.g001

In our experiments, we have only used samples from AML patients that did not display cell death after thawing over 10% as checked by blue trypan labeling. After thawing, cells were cultured in IMDM without serum for 2 h and then allowed to adhere on fibronectin. At the end of 4 h adhesion, culture medium was supplemented by SVF to maintain the cells until 24 h. Cell survival of AML blasts from patients was measured at 24 h by MTT labeling. Measurement of apoptosis in AML blasts treated or not by TNFα was realized by FACS using labeling by APO2.7 (AP02.7–PC5 monoclonal antibody from Immunotech, Marseille, France), a mitochondrial membrane protein expressed during the early stages of apoptosis in relation to the release of cytochrome C outside the mitochondria. APO2.7 labeling has been chosen since in our control apoptotic assays performed with damaurotinucin we detected interference with the Annexin-V fluorescence (not shown). In our experimental conditions, spontaneous death after thawing was maximally 20% at 24 h (not shown).

Subcellular fractionation and α5 immunoprecipitation

Culture dishes were coated overnight at 4°C with 40 μg/ml of human fibronectin in a final volume of 10 ml of PBS and subsequently blocked with 1% fatty acid-free BSA in PBS, 1 h at room temperature. 30×10⁶ cells were serum starved for 1 h at 37°C, then allowed to adhere to fibronectin-coated dishes for 1 h at 37°C, or maintained in suspension.

For subcellular fractionation, after washing, cells were pelleted by centrifugation (5 min, 100 g) and resuspended in a hypotonic buffer [10 mM HEPES (pH 7.2), 10 mM KCl, 1.5 mM MgCl₂, 0.1 mM EGTA, 20 mM NaF, 100 μM Na₃VO₄, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF (Phenylnemethanesulfonyl fluoride)] for 30 minutes at 4°C, with shaking. Cells were broken up using a Dounce homogenizer (90 strokes), after which the nuclei were pelleted by centrifugation (10 min, 1100 g, 4°C). The nuclei-free supernatant was subjected to a second 15000 g centrifugation for 45 min at 4°C to separate the membranes from the cytosolic fractions. The membrane pellets were resuspended in lysis buffer [10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, and 1% Triton X-100] and sonicated 1 minute. 50 μg of total cytosolic and membrane pellet proteins were analysed by Western blotting.

For immunoprecipitation of α5 integrin, at the end of adhesion, cells were washed in PBS and lysed in a buffer containing 20 mM Tris HCl pH 8, 130 mM NaCl, 1% Triton X-100, 10% glycerol, orthovandate and protease inhibitors. After sonication and centrifugation at 15000 g, supernatant was processed for protein quantification, preclearing and incubation overnight with 20 μL α5 polyclonal antibodies. Then, immunoprecipitates were recovered with protein A sepharose, washed and analysed by Western blotting.

Statistical analysis

Student’s t test was used for statistical analysis of n independent experiments realized in vitro.

Results

GSK3β, α4β1 and α5β1 integrins are implicated in cell survival of serum-starved adherent leukemic cells

We have previously demonstrated that α4β1 and α5β1, the integrins, and the kinase GSK3β, regulate the chemosensitivity of adherent leukemic cells onto fibronectin [8]. Using a siRNA approach, we show that survival of adherent U937 on fibronectin in serum-starved conditions involves both GSK3β and β1 integrins (α4β1 and α5β1) (Fig. 1A). Decreased expression of GSK3β (70±10%), of α4β1 (33±10%) and of α5β1 (47±5%) was assessed by Western blotting (Fig. 1B). None of these siRNA altered the adhesive capacities of leukemic cells (Fig. 1B). Viable cell recovery 24 hours after adhesion assay on fibronectin measured by MTT labeling was increased in adhesion conditions compared to suspension (Fig. 1A, 18±6%, p<0.01), GSK3β and α5β1 siRNA induced a 30±5% decrease of cell recovery in adhesion (p<0.001), whereas α4β1 siRNA was less potent (18±5%, p<0.05). No significant changes occurred in suspension upon treatment with the different siRNAs. Of note, identical results were obtained with two sources of siRNA targeting different sequences of α4 and α5 integrin genes (not shown).

Since MTT measurement could be the result of both cell survival and proliferation, apoptotic cell death was assessed after adhesion assay by annexin labeling (Fig. 1A). Whereas MTT measurement at 24 hours may reflect both apoptotic and necrotic processes, annexin labeling was realized at 5 hours to check specifically for the occurrence of apoptosis. A higher level of apoptosis was detected in U937 electroporated with control siRNA comparatively to untreated cells (20±2% versus 5±10%). Adhesion decreased the amount of annexin-positive cells compared to suspension (24±4%, p<0.05). Downregulation of α4β1 or α5β1 expression in adherent U937 induced an increase of apoptotic cells compared to control siRNA in adhesion (69±5% p<0.01 and 44±6% p<0.05, respectively). Knockdown of GSK3β expression increased apoptosis of adherent U937 (81±4%, p<0.01). Apoptosis in suspension was not significantly changed after treatment with integrin siRNAs.

Using the pharmacological GSK3β inhibitor SB216763 at a concentration (10 μM) without deleterious quantitative effect on cell adhesion (Fig. 1B), we have further demonstrated that, as well as in U937, the GSK3β-dependent survival pathway occurred in adherent leukemic cells from patients but not in the HL-60 and KG1 leukemic cell lines (Fig. 1C). Accordingly, the activated form of GSK3β (dephosphorylated Ser-9 GSK3β) was increased in adherent U937 and cells from AML patients, but not in adherent
HL-60 and KG1 cells (Fig. 1D). Importantly, GSK3β-dependent cell survival was found in adherent AML cells classified along different FAB. However the pro-apoptotic response to SB216763 occurred in 50% AML samples of the cohort (n = 16; 3 FAB0, 4 FAB1, 2 FAB2, 3 FAB4 and 4 FAB5) and was more pronounced in AML from myelomonocytic FAB (Fig. 1C). Furthermore, most of the blasts underwent CAM-DR in vitro and SB216763 abolished it, as previously described [8].

Altogether, these results demonstrate that engagement of α4β1 and α5β1 integrins to fibronectin supports cell survival of serum-starved adherent leukemic cells, potentially through activation of GSK3β via its dephosphorylation.

The inhibitory Ser-9 phosphorylation of GSK3β is differentially regulated by α4β1 and α5β1 integrins

To further demonstrate that GSK3β is involved in α4β1 and α5β1-mediated prosurvival effect, we used siRNA to knockdown integrin expression (Fig. 2A). We have studied consequences of the decrease in expression of each integrin on GSK3β phosphorylation state (Fig. 2B). SiC = non-targeting siRNA. Right panel shows the mean ± S.E.M. variations of the P(S9)GSK3β/GSK3β ratio analyzed by densitometry from three independent experiments.

Figure 2. GSK3β is differentially regulated by α4β1 and α5β1 integrins in leukemic cells. A- Specificity and efficacy of siRNA integrins were checked by Western blot. B- Serum-starved U937 were allowed to adhere on fibronectin for 1 h and the Ser-9 phosphorylation state of GSK3β was compared to cells in suspension after downregulation of α4 and α5 expression by siRNA. SiC = non-targeting siRNA. Right panel shows the mean ± S.E.M. variations of the P(S9)GSK3β/GSK3β ratio analyzed by densitometry from three independent experiments. C- The phosphorylation state of GSK3β was studied in suspension or after adhesion of U937 on surfaces coated with fibronectin (Fn, 40 μg/ml), anti-α4 (1 μg/ml) or -α5 (clone P1D6 0.1 μg/ml; clone JBS5 0.2 μg/ml) antibodies in experimental conditions as for B. Adhesive capacities of U937 in each condition of coating were measured by colorimetry and are shown on right panel. Data are representative of three independent experiments.

doi:10.1371/journal.pone.0009807.g002
tion. In serum-starved conditions, α4 and α5 siRNA had different effects on the inhibitory Ser-9 phosphorylation of GSK3β (Fig. 2B). Ser-9 phosphorylation of GSK3β was decreased (50% ± 17, p<0.05) upon adhesion to fibronectin compared to suspension cells. Whereas α5 siRNA abolished the Ser-9 dephosphorylation of GSK3β in adhered cells, α4 siRNA had no significant effect on Ser-9 phosphorylation. Conversely, in suspension, none of integrin siRNA modified significantly Ser-9 phosphorylation of GSK3β.

These results are in favor of GSK3β activation through Ser-9 dephosphorylation after α5β1 engagement onto fibronectin.

Since we have previously shown that adhesion to surfaces coated with anti-α4 (clone P4G9) or -α5 (clone P1D6) stimulatory antibodies supported the chemoresistance of U937 cells [8], we studied GSK3β phosphorylation in U937 adhered (with the same efficiency) either to fibronectin or to α4 or α5 antibodies (Fig. 2C). Adhesion of U937 to coated anti-α5 antibodies induced a decrease of Ser-9 phosphorylation of GSK3β compared to suspended cells (60% ± 10, p<0.01), thus mimicking the observations after adhesion of leukemic cells on fibronectin. However, specific engagement of α4β1 onto coated anti-α4 antibodies did not

Figure 3. α5 integrin, PP2A and GSK3β are co-localized in adherent leukemic cells. A- The Ser-9 phosphorylation of GSK3β was studied by Western blot in cytosolic (Ct) and membrane (Mb) compartments of U937 in adhesion or in suspension. B- The presence of GSK3β (and its Ser-9 phosphorylated form), PP2A (and its Tyr-307 phosphorylated form), the scaffolding protein RACK1 and the PI 3-kinase regulatory subunit p85 was checked by Western blot in α5 immunoprecipitates from U937 in suspension (Susp.) or in adhesion (Adh.). The absence of flotillin in α5 immunoprecipitate demonstrates specificity of the interactions between α5 integrin, PP2A and GSK3β. Right panel (input) indicates the amounts of α5 subunit and GSK3β proteins in the total lysates (Total) and in the supernatants (Sup.), before and after immunoprecipitation of α5 respectively. Data are representative of three independent experiments.

doi:10.1371/journal.pone.0009807.g003
significantly change the phosphorylation status of GSK3β compared to suspension (10%±15). Interestingly, adhesion of U937 to coated anti-α5 antibody clone JBS5 induced a strong adhesion without cell spreading by contrast with fibronectin and clone P1D6 (not shown and [25]) but was not efficient to trigger GSK3β dephosphorylation (Fig. 2C). Of note, adhesion of U937 on non-specific Ig did not induce changes in phosphorylation of GSK3β nor in cell survival (not shown and [8]).

These data unravel a differential control of Ser-9 phosphorylation of GSK3β by α5β1 and α3β1 integrins, allowing activation of the enzyme. However, upon adhesion of serum-starved leukemic cells on fibronectin, α5β1 alone seems to support GSK3β activation.

Involved of PP2A in α5β1-mediated GSK3β activation and cell survival

The phosphatase PP2A is a partner of β1 integrins in the control of cell survival [26] and regulates Ser-9 phosphorylation of GSK3β [7]. As shown in Fig. 3A, the inhibitory Ser-9 phosphorylation of GSK3β in the cytosolic/membrane fraction was found to be strongly decreased in adhesion compared to suspension. Moreover, the active form of GSK3β (Ser-9 dephosphorylated GSK3β) was increased in α5 integrin immunoprecipitate from adherent U937 comparatively to suspension and was found associated with PP2A (Fig. 3B). PP2A was poorly phosphorylated on its inhibitory site (Tyr-307 in α5) immunoprecipitate from adherent U937. Interestingly, adhesion of U937 on fibronectin triggered the association of the scaffolding protein RACK1 with α5 whereas it decreased the amount of the P1 3'-kinase regulatory subunit p85 associated with the integrin (Fig. 3B). These data show that GSK3β is co-localized with α5 integrin in a molecular complex containing phosphatases and kinases potentially implicated in its regulation.

To further demonstrate that PP2A could play a role in GSK3β activation, we used okadaic acid (OA) to inhibit PP2A [26]. The inactive phosphorylated forms of PP2A and GSK3β (phosphoTyr-307 PP2A and phosphoSer-9 GSK3β, respectively) were decreased upon adhesion but restored upon treatment with OA (Fig. 4A) showing that the activation of the two enzymes were correlated. Of note, under treatment by OA, a decrease of GSK3β expression was constantly measured (Fig. 4A) suggesting its Ser-9 phosphorylation-dependent proapoptotic degradation as demonstrated previously [27]. The PP2A regulatory subunit B' (also called B56 or PR61) is responsible for the function of PP2A in cytoskeletal stability [28] and Akt regulation [29], potentially involved in the control of cell survival and GSK3β regulation. Indeed we have measured a decrease of the active form of Akt (ThrERrone 308 phosphorylated Akt) concomitantly with the activation of PP2A and GSK3β in adherent leukemic cells (Fig. 4A). As shown in Fig. 4B, a decrease of α5β1 and PP2A-B' (40%±5) expression by siRNA both triggered an increase in Ser-9 phosphorylation of GSK3β suggesting their roles in keeping GSK3β in an active state. The PP2A inhibitor OA decreased survival of adherent U937 (35%, p<0.05) to the same extent as α5β1 knockdown (Fig. 4C). SiRNA directed against the PP2A regulatory subunit B' induced a moderate but significant survival decrease (14%, p<0.05 statistical apprared test) in adhesion (Fig. 4C). In suspension, leukemic cells were not significantly affected under these conditions (not shown). An increase of AML cell survival was measured upon adhesion on fibronectin (27%±6) or α5 antibody (clone P1D6, 46%±3) but not α2 antibody (clone P4G9, 10%±7) compared to suspension. This improvement of AML cell survival upon adhesion was abolished by OA treatment (Fig. 4C).

These data show a role for PP2A in GSK3β activation and cell survival of adherent leukemic cells.

Altogether, these data show that PP2A is activated in serum-starved adherent leukemic cells and cooperate with α5β1 integrin in leukemia cell survival through the regulation of GSK3β.

α5β1 and GSK3β regulate TNFα resistance and both extrinsic and intrinsic apoptotic pathways in leukemic cells

We have previously shown that both α5β1 and α3β1 integrins supported chemoresistance of U937 cells [8]. Since GSK3β activation is α5β1 integrin-dependent in our conditions and has been shown to play a specific pro-survival role through the response to death receptor activation [21], we checked whether α5 and α3 integrins could be differentially involved in TNFα response. The incubation of U937 with TNFα in serum-starved suspension conditions induced a 44%±3 (p<0.01) decrease in cell survival (Fig. 5A). Adherent U937 were more resistant to this treatment since a decrease of 24%±4 (p<0.01) of cell survival was measured. α5 siRNA as well as GSK3β siRNA, but not α3 siRNA, abolished the adhesion-dependent resistance to TNFα (Fig. 5A).

The GSK3β-dependent TNFα resistance and NF-κB activation [8] in adherent leukemic cells suggest that both extrinsic and intrinsic apoptotic pathways could be regulated by α5β1 integrin engagement. Indeed the treatment of U937 cells with siRNA directed to α5 or GSK3β induced a cleavage of caspase 8 and an increase of cytosolic cytochrome C in favor of the activation of both apoptotic pathways in adherent leukemic cells treated by TNFα. As a result of both apoptotic pathways, caspase 3 was cleaved upon this treatment (Fig. 5B). Protection against TNFα conferred by α5-dependent adhesion and activated GSK3β was confirmed in AML patient (Fig. 5B).

Thus, these data demonstrate that the engagement of α5β1 integrin and GSK3β activation both support resistance to extrinsic and intrinsic pro-apoptotic pathways of serum-starved adherent leukemic cells.

Discussion

In this work, we have demonstrated that adhesion to fibronectin triggers a specific survival signaling pathway in U937 leukemic cells upon serum starvation. Importantly, this survival pathway occurs in leukemic blasts from AML patients and supports their chemoresistance [8]. The survival advantage conferred by adhesion to serum-starved leukemic cells requires the activation of GSK3β. A signaling cascade involving the α5β1 integrin and the phosphatase PP2A is responsible for Ser-9 dephosphorylation and thus activation of GSK3β.
In adherent conditions, co-localization of GSK3β and PP2A with α5 integrin in the membrane compartment correlated with Ser-9 dephosphorylation of GSK3β suggesting the activation of the enzyme under these conditions. Indeed, inhibition of α5β1 and α4β1 by siRNA or pharmacological drugs induced an increase of the Ser-9 phosphorylated inhibited form of GSK3β. The β1 integrin regulates the response to TNFα and both extrinsic and intrinsic apoptotic pathways in adherent leukemic cells. A - U937 transfected with α4, α5 or GSK3β siRNA in suspension or adhesion were treated with TNFα (10 ng/ml) for 4 hours and cell survival assays (MTT) were performed as described for Fig. 1. Mean ± S.E.M. n = 3, *P<0.05 **P<0.01. Right panel shows the efficacy of siRNA directed to GSK3β, α4 and α5 integrins. B - Extrinsic (caspase-8) and intrinsic (cytochrome C) or both (caspase-3) apoptotic pathways were studied by Western blotting in TNFα-treated adherent U937 treated with siRNA against α5 or GSK3β. SIC = Sicontrol, representative of three independent experiments. On the right side is shown cell apoptosis (APO2.7 labeling) measured in TNFα-treated blasts from AML patients in suspension or in adhesion on fibronectin or on P1D6 α5 antibody as described in the legend of Fig. 2 (n = 2 FAB5, mean ± S.D., *P<0.05). The treatment with the GSK3β inhibitor SB216763 was performed as described for Fig. 1. doi:10.1371/journal.pone.0009807.g005
integrin/PP2A pathway of GSK3β activation may be specific of some integrin heterodimers since it has been demonstrated downstream of α3β1 [3], α5β1 but not α6β1 engagement. Moreover, in our experiments, serum starvation was required to trigger the integrin-dependent GSK3 activation (not shown). The α6β4/GSK3β pathway supports 30% of survival in adherent leukemic cells. Interestingly, we have previously implicated this survival pathway in cell adhesion-mediated drug resistance, where it was shown to allow a 30% increase in survival [8]. Our data also demonstrate that the α6β4/GSK3β pathway is involved in TNFα resistance, caspase 8 and cytochrome C regulation, and activation of the transcriptional factor NF-κB [3]. Thus, α6β4-mediated activation of GSK3β modulates both extrinsic and intrinsic apoptosis signaling pathways [15].

The α6β4/GSK3β pathway could modulate diverse signaling pathways controlling cell survival. ERK activation has been described to control cell survival that is linked to integrin engagement upon serum starvation [30] or Fas stimulation [26]. Moreover, GSK3β regulates MEK1/2 demonstrating its implication in the stress-activated protein kinase pathway [31]. In our experiments, ERK or p38 inhibition did not influence cell survival (not shown). Interestingly, the activity of c-Jun N-terminal kinase (JNK), which is found constitutively activated in most patients with acute myeloid leukemia, has been correlated with a multistage anthracycline resistance [32] and controls fibronectin survival signaling under serum-starvation conditions [33]. Our preliminary data suggest that JNK is activated in adherent U937. It remains to determine whether, in our experimental model, JNK activation is modulated by GSK3β.

Our data show that adhesion of U937 on fibronectin triggers the association of the scaffolding protein RACK1 with α6β4. Interestingly, RACK1 has been described as a signal integrator between growth factor receptor and β1 integrin [34]. PP2A and the PI 3-kinase regulatory subunit p85 are among the proteins whose recruitment and dissociation are modulated by RACK1. In our experiments, both an increase of activated GSK3β and a decrease of p85 were observed in α6 integrin-immunoprecipitate from adherent U937. This result suggests that the integrin-dependent activation of GSK3β could result from both increased PP2A and decreased PI 3-kinase/Akt activities [5]. Accordingly we measured a concomitant decrease of the active form of Akt with GSK3β activation in adherent leukemic cells. Thus, survival of U937 in starved conditions may be linked to a quiescence status with decreased proliferative and migration capacities [35]. However, the organization of the cytoskeleton seems to play a key role for the α6β4-dependent activation of GSK3β since adhesion through the α6β4 antibody clone JBS5 impaired specifically cell spreading and did not trigger GSK3β activation. Whether RACK1 directly regulates PP2A activity or targets GSK3β and PP2A catalytic/regulatory units to specific locations is an open question. Interestingly, it has been shown that RACK1 is a component of the signaling pathway of the p55 TNF receptor [36] and is implicated in the resistance to apoptotic stimuli in hematopoietic cells [37]. Thus, RACK1 could regulate the death-antagonizing complex involving GSK3β at TNF receptor [21].

We have previously shown [9] that engagement of both α6β4 and α5β1 supported cell-adhesion mediated drug resistance of U937. However, α6β4 alone was shown to activate GSK3β and TNFα resistance. Our unpublished data demonstrate that α6β4 integrin controls U937 survival in adhesion through the tyrosine kinase Pyk2 activation. It suggests that α6β4/GSK3β and α6β4/Pyk2-dependent pro-survival pathways could cooperate through the activation of specific pathways of resistance to extrinsic and intrinsic pro-apoptotic pathways. Interestingly, our preliminary data show that the α6β4/Pyk2 cell survival pathway in adherent U937 involves PI 3-kinase activation and Bcl-xL expression. Since we have shown that the GSK3β-dependent survival pathway occurred in U937 but not in HL-60 and KG1 cell lines, it could be interesting to compare their α6 or α5-dependent adhesive capacities. Notably, and by contrast with U937, RACK1 increase and PI 3-kinase subunit p85 decrease were not observed in α6 integrin-immunoprecipitates from adherent HL-60 (not shown). However, we demonstrate that AML cells from patients classified along different FAB trigger mostly the GSK3β-dependent survival pathway upon adhesion onto fibronectin. Except a myelomonocytic phenotype, this survival pathway was not correlated with other clinico-biological parameters in patients.

In conclusion, we propose GSK3β activation as a new adhesion-dependent cell survival pathway that is regulated by the engagement of specific integrin heterodimers. It could control a pro-survival response to death receptors but also intrinsic pro-survival pathways under stress conditions. Importantly, the pro-survival GSK3β-dependent pathway may represent a new therapeutic target in cancer cells whose resistance to therapy is supported by cell adhesion.

Acknowledgments

The authors acknowledge the plateau de cytometrique in IFR150 and Drs Michele Allouche and Kelly Thornber for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: FDTC MD EB LY BP CRS. Performed the experiments: FDTC MD JB CRS. Analyzed the data: FDTC JB EB LY CRS. Wrote the paper: FDTC BP CRS.

References

1. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95–102.
2. Dajani R, Fraser E, Roe SM, Young N, Good V, et al. (2001) Crystal structure of glycogen synthase kinase 3 beta: structural basis for substrate specificity and autoinhibition. Cell 105: 721–732.
3. Novak A, Hsu SC, Leung-Hagesteijn C, Radeva G, Papkoff J, et al. (1998) Cell biology and biochemistry of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J Biol Chem 280: 22044–22052.
4. De Toi F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, et al. (2006) A crosstalk between the Wnt and the adhesion-dependent signalling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113–3122.
5. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal niche. Nat Biotechnol 25: 1315–1321.
6. Ayala F, Dewar R, Kirran M, Kalluri R (2009) Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23: 2223–2243.
7. Lee YI, Seo M, Kim Y, Kim SY, Kang UG, et al. (2005) Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J Biol Chem 280: 22044–22052.
8. De Toi F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, et al. (2006) A crosstalk between the Wnt and the adhesion-dependent signalling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113–3122.
9. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal niche. Nat Biotechnol 25: 1315–1321.
10. Ayala F, Dewar R, Kirran M, Kalluri R (2009) Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23: 2223–2243.
11. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD (2007) Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of
25. Bao W, Stro¨mblad S (2002) Use of an Immobilized Monoclonal Antibody to

24. Kapur R, Cooper R, Zhang L, Williams DA (2001) Cross-talk between

23. Hazlehurst LA, Landowski TH, Dalton WS (2003) Role of the tumor

22. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, et al. (2008) 

21. Sun M, Song L, Li Y, Zhou T, Jope RS (2008) Identification of an antiapoptotic

20. Ougolkov AV, Billadeau DD (2006) Targeting GSK-3: a promising approach

19. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, et al. (2005) 

18. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD 

17. Ghosh JC, Altieri DC (2005) Activation of p53-dependent apoptosis by acute

16. Liao X, Zhang L, Tharsher JB, Du J, Li B (2005) Glycogen synthase kinase- 

15. Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of

14. Deng J, Xia W, Miller SA, Wen Y, Wang HY, et al. (2004) Crossregulation of

13. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, et al. (2000) Requirement for

12. Steinbrecher KA, Wilson W, 3rd, Cogswell PC, Baldwin AS (2005) Glycogen 

11. Steinbrecher KA, Wilson W, 3rd, Cogswell PC, Baldwin AS (2005) Glycogen 

10. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD 

9. Van Kanegan MJ, Adams DG, Wadzinski BE, Streack S (2005) Distinct protein 

8. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD 

7. Van Kanegan MJ, Adams DG, Wadzinski BE, Streack S (2005) Distinct protein 

6. Chetoui N, Geudron S, Chamoux E, Aoudjit F (2006) Collagen type Imediated 

5. Kiely PA, Leahy M, O'Gorman D, O'Connor R (2005) RACK1-mediated 

4. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, et al. (2000) Matrix survival 

3. Van Kanegan MJ, Adams DG, Wadzinski BE, Streack S (2005) Distinct protein 

2. Kapur R, Cooper R, Zhang L, Williams DA (2001) Cross-talk between

1. Steinbrecher KA, Wilson W, 3rd, Cogswell PC, Baldwin AS (2005) Glycogen 

GSK3β in Adhesion and Survival